Evotec AG (NASDAQ:EVTCY)‘s stock had its “sell” rating reaffirmed by investment analysts at DZ Bank AG in a research note issued to investors on Thursday.

Several other brokerages also recently commented on EVTCY. Berenberg Bank downgraded shares of Evotec AG from a “buy” rating to a “hold” rating in a research note on Tuesday, June 6th. Deutsche Bank AG restated a “neutral” rating on shares of Evotec AG in a research note on Wednesday, May 3rd.

Evotec AG (EVTCY) traded up 0.61% during mid-day trading on Thursday, hitting $36.22. 4,413 shares of the company were exchanged. The company has a market cap of $2.66 billion and a price-to-earnings ratio of 62.02. The stock’s 50 day moving average is $31.00 and its 200-day moving average is $24.47. Evotec AG has a 12-month low of $9.79 and a 12-month high of $36.28.

Evotec AG (NASDAQ:EVTCY) last issued its earnings results on Thursday, August 10th. The company reported $0.04 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.03. The firm had revenue of $58.52 million for the quarter, compared to the consensus estimate of $50.06 million.

ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/20/dz-bank-ag-reiterates-sell-rating-for-evotec-ag-evtcy.html.

Evotec AG Company Profile

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.